Ceritinib (LDK378)

Catalog No.S7083

Ceritinib (LDK378) Chemical Structure

Molecular Weight(MW): 558.14

Ceritinib (LDK378) is potent inhibitor against ALK with IC50 of 0.2 nM in cell-free assays, shows 40- and 35-fold selectivity against IGF-1R and InsR, respectively. Phase 3.

Size Price Stock Quantity  
USD 147 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 19 Publications

Purity & Quality Control

Choose Selective ALK Inhibitors

Biological Activity

Description Ceritinib (LDK378) is potent inhibitor against ALK with IC50 of 0.2 nM in cell-free assays, shows 40- and 35-fold selectivity against IGF-1R and InsR, respectively. Phase 3.
Features Does not cross react with c-Met, and has an improved in vivo glucose homeostasis profile relative to TAE684. May be active in Crizotinib-relapsed tumors.
Targets
ALK [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IGF-1R [1]
(Cell-free assay)
0.2 nM 7 nM 8 nM
In vitro

LDK378 shows great anti-proliferative activity in Ba/F3-NPM-ALK and Karpas290 cells with IC50 of 26.0 nM and 22.8 nM, compared with IC50 of 319.5 nM and 2477 nM in Ba/F3-Tel-InsR and Ba/F3-WT cells. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Parental(+IL3) NEfaRopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXm3NkBp MnjjSG1UVw>? M{PBfGlEPTB;MUW4OkDDuSBzN{Ogcm0> NGTO[48zPTd2OUCzOC=>
WT 70 MmLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXiUVRpPzJiaB?= M4LsPGROW09? MYPJR|UxRTJzINMxJFghdk1? NFnkU4UzPTd2OUCzOC=>
G1128S 1022 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rieVczKGh? MnHQSG1UVw>? M{DFfGlEPTB;MUCyJOKyKDN6IH7N MVOyOVc1QTB|NB?=
C1156F 1293 NIXQSZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX35O2VzPzJiaB?= MmDZSG1UVw>? NULiWo1GUUN3ME2yNVchyrFiMUG1JI5O NUHnTVlqOjV5NEmwN|Q>
I1171N 519 MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXu3NkBp NVrzUG1NTE2VTx?= MVrJR|UxRTF6NzFCtUA5PyCwTR?= MkTjNlU4PDlyM{S=
I1171T 445 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fzTFczKGh? M3TMSWROW09? NYPOXVhEUUN3ME24NkDDuSBzMjDuUS=> MoDkNlU4PDlyM{S=
F1174I 184 Ml;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXP0OJh7PzJiaB?= M3e3cWROW09? M{XmcmlEPTB;MUOgxtEhOC5zIH7N NX60NpQxOjV5NEmwN|Q>
N1178H 169 NVrBTJRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX63NkBp MVXEUXNQ M1S5U2lEPTB;NEKgxtEhPiCwTR?= NEjiPYozPTd2OUCzOC=>
E1210K 748 NGXZeWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\kblczKGh? NI\MPZRFVVOR NHjlUG5KSzVyPUG4O{DDuSB6NDDuUS=> NGO3VGozPTd2OUCzOC=>
C1156F/D1203N 2809 M{X4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\HWVczKGh? M{Hj[mROW09? NEe1d5RKSzVyPUK1OEDDuSB7OTDuUS=> M3jwUFI2PzR7MEO0
Ba/F3 NA WT NVrub2dKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3yxWVczKGh? M3rRdWlEPTB;MD6wNlAh|ryP NHPEfZMzPTd{N{SwNC=>
Ba/F3 NA C1156Y M1vTVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnToO|IhcA>? NXGxOJJwUUN3ME2wMlA4OSEQvF2= MoDRNlU4Ojd2MEC=
Ba/F3 NA L1196M MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH21XGk4OiCq NUPLR29ZUUN3ME2wMlA1OiEQvF2= MkLnNlU4Ojd2MEC=
Ba/F3 NA L1152R NFHNWWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUm3NkBp MkO5TWM2OD1yLkK4PEDPxE1? NYC4eJFEOjV5Mke0NFA>
Ba/F3 NA G1202R M1vIPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXO3NkBp M3W3PGlEPTB;MD6yO|ch|ryP NIfERZQzPTd{N{SwNC=>
Ba/F3 NA G1269A MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXHOohoPzJiaB?= NIT5d2NKSzVyPUCuNFE6KM7:TR?= NHXvUYIzPTd{N{SwNC=>
Ba/F3 NA S1206Y NYjMWpBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHS3OIo4OiCq MVXJR|UxRTBwMEO3JO69VQ>? M2OwSVI2PzJ5NECw
Ba/F3 EA WT NILPWFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjub29tPzJiaB?= Mm\WTWM2OD1yLkCyNUDPxE1? M3rjbVI2PzJ5NECw
Ba/F3 EA C1156Y M17TOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXy2e25RPzJiaB?= MlXNTWM2OD1yLkCyOkDPxE1? NWDWcIE2OjV5Mke0NFA>
Ba/F3 EA L1196M NYezUVdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH:wW4U4OiCq NF7xUWxKSzVyPUCuNFE6KM7:TR?= M{LveVI2PzJ5NECw
Ba/F3 EA L1152R NHTieFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHkS49FPzJiaB?= MmGzTWM2OD1yLkC5PUDPxE1? MlrwNlU4Ojd2MEC=
Ba/F3 EA G1202R NFXCZ25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fXc|czKGh? MnKyTWM2OD1yLkS2O{DPxE1? NEX4cXgzPTd{N{SwNC=>
Ba/F3 EA G1269A MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF73R4k4OiCq MWjJR|UxRTBwMEOzJO69VQ>? MV6yOVczPzRyMB?=
Ba/F3 EA S1206Y NV3RUVlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DhT|czKGh? MUjJR|UxRTBwMEO4JO69VQ>? MoPwNlU4Ojd2MEC=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-ALK / ALK / p-AKT / AKT / p-ERK / ERK; 

PubMed: 28425916     


Inhibition of ALK autophosphorylation and downstream signaling by ceritinib, crizotinib and PF06463922 in NB-1 cells. Cells were harvested after treatment for 4 hr with the indicated compounds at different concentrations. Whole cell lysates were analyzed by Western blotting to detect the levels of ALK, AKT and ERK proteins and their phosphorylation.

pROS1 / ROS1 / pSTAT3 / STAT3 ; 

PubMed: 25351743     


Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins.

28425916 25351743
Growth inhibition assay
Cell viability; 

PubMed: 29067644     


The effects of ceritinib treatment on cell viability in ARMS and ERMS cell lines. Cells were treated with 0-5 μM ceritinib for 72 h (Rh30, RD), 120 h (Rh41), or 144 h (Rh18, Aska) and cell viability was assessed. The y-axis represents relative cell viability compared to non-treated cells (control). Effects on cell viability were determined in triplicate. Values are presented as mean ± SD. Dotted line represents the IC50-value. The human synovial sarcoma cell line Aska with constitutive ALK phosphorylation was used as a positive control.

29067644
In vivo LDK378 is designed to reduce the possibility of forming reactive metabolites and shows undetectable levels of glutathione (GSH) adducts (<1%) in liver microsomes. LDK378 has relatively good metabolic stability, with moderate CYP3A4 (Midazolam substrate) inhibition and hERG inhibition. LDK378 exhibits low plasma clearance in animals (mouse, rat, dog and monkey) compared to liver blood flow, with the oral bioavailability of above 55% in mouse, rat, dog and monkey. LDK378 induces a dose-dependent growth inhibition and tumor regression in the Karpas299 and H2228 rat xenograft models, with no body-weight loss. LDK378 shows no impact on insulin levels or plasma glucose utilization in the mouse upon chronic dosing up to 100 mg/kg. [1]

Protocol

Kinase Assay:[1]
+ Expand

Enzymatic kinase profiling description:

All kinases are expressed as either Histidine- or GST-tagged fusion proteins using the baculovirus expression technology except for the untagged ERK2 which is produced in E. coli. The kinase activity is measured in the LabChip mobility shift assay. The assay is performed at 30°C for 60 min. The effect of LDK378 on the enzymatic activity is obtained from the linear progress curves in the absence and presence of LDK378 and routinely determines from one reading (end point measurement)
Cell Research:[1]
+ Expand
  • Cell lines: Ba/F3-NPM-ALK, Ba/F3-Tel-InsR, Ba/F3-WT, Karpas299 cells
  • Concentrations: ~100 μM
  • Incubation Time: 2-3 days
  • Method: Luciferase-expressing cells are incubated with serial dilutions of LDK378 or DMSO for 2-3 days. Luciferase expression is used as a measure of cell proliferation/survival and is evaluated with the Bright-Glo Luciferase Assay System. IC50 values are generated by using XLFit software.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: RNU nude rats bearing the Karpas299/H2228 tumors
  • Formulation: LDK378 (phosphate salt) formulated in 0.5% methylcellulose/0.5% Tween 80
  • Dosages: ~50 mg/kg
  • Administration: Oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL warmed (35.83 mM)
Ethanol 3 mg/mL (5.37 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 558.14
Formula

C28H36ClN5O3S

CAS No. 1032900-25-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02450903 Completed Drug: LDK378 Non-Small-Cell Lung Cancer Novartis Pharmaceuticals|Novartis August 21 2015 Phase 2
NCT02276027 Recruiting Drug: BYL719|Drug: INC280|Drug: LDK378|Drug: MEK162 Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma Novartis Pharmaceuticals|Novartis January 20 2015 Phase 2
NCT02040870 Completed Drug: LDK378 Non-Small Cell Lung Cancer Novartis Pharmaceuticals|Novartis March 7 2014 Phase 1|Phase 2
NCT01950481 Completed Drug: LDK378 Normal Hepatic Function|Impaired Hepatic Function Novartis Pharmaceuticals|Novartis January 2014 Phase 1
NCT01772797 Completed Drug: LDK378|Drug: AUY922 Anaplastic Lymphoma Kinase (ALK)|Non-small Cell Lung Cancer Novartis Pharmaceuticals|Novartis June 2013 Phase 1
NCT01685060 Completed Drug: LDK378 Non-Small Cell Lung Cancer Novartis Pharmaceuticals|Novartis November 26 2012 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    how to reconstitute the inhibitor for oral administration to mice?

  • Answer:

    You can resuspend LDK378 in 30% PEG400/0.5% Tween 80/5% propylene glycol and use the suspension for oral gavage feeding.

ALK Signaling Pathway Map

ALK Inhibitors with Unique Features

Related ALK Products

Tags: buy Ceritinib (LDK378) | Ceritinib (LDK378) supplier | purchase Ceritinib (LDK378) | Ceritinib (LDK378) cost | Ceritinib (LDK378) manufacturer | order Ceritinib (LDK378) | Ceritinib (LDK378) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID